Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2010-4-13
pubmed:abstractText
The ZMR porous stem is a modular cylindrical porous-coated femoral stem for revision THA. The objective of this study was to evaluate the clinical and radiographic outcomes of this stem at midterm followup. We prospectively reviewed 69 patients (72 femoral revisions) treated with the stem. The indication for revision was aseptic loosening in 61 (85%), periprosthetic fractures in five (7%), infection in three (4%), dislocation in two (3%), and fractured stem in one (1%). Minimum followup was 60 months (mean, 85 months; range, 60-114 months). The survival rate with revision for any reason as an end point was 93.8%. Mean preoperative Harris hip score was 39 points, and mean Harris hip score at last followup was 72 points. Four (5.5%) stems required rerevision, two (2.8%) for loosening, one (1.4%) for fracture at the modular junction, and one (1.4%) for infection. Subsidence occurred in eight (11%) patients, in the range of 5 to 25 mm. Two (2.89%) of the stems that subsided were symptomatic and progressive. The ZMR porous stem is a versatile system that offers a reliable fixation and an off-the-shelf solution for a multitude of femoral reconstruction challenges. Level of Evidence: Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-10611878, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-10653112, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-10829167, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-11451971, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-11451973, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-11764349, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-12068425, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-12730939, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-12730940, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-12730941, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-14646718, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-15057089, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-15057091, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-15577490, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-15577492, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-16435360, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-17312593, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-17891035, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-18280416, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-18534480, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-18972178, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-3416519, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-4030826, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-5783851, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-7744913, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-8613438, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-9128770, http://linkedlifedata.com/resource/pubmed/commentcorrection/19533262-9458248
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1528-1132
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
468
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1310-5
pubmed:dateRevised
2011-7-28
pubmed:meshHeading
pubmed-meshheading:19533262-Adult, pubmed-meshheading:19533262-Aged, pubmed-meshheading:19533262-Aged, 80 and over, pubmed-meshheading:19533262-Arthroplasty, Replacement, Hip, pubmed-meshheading:19533262-Coated Materials, Biocompatible, pubmed-meshheading:19533262-Female, pubmed-meshheading:19533262-Femur, pubmed-meshheading:19533262-Follow-Up Studies, pubmed-meshheading:19533262-Hip Prosthesis, pubmed-meshheading:19533262-Humans, pubmed-meshheading:19533262-Male, pubmed-meshheading:19533262-Middle Aged, pubmed-meshheading:19533262-Porosity, pubmed-meshheading:19533262-Prospective Studies, pubmed-meshheading:19533262-Prosthesis Design, pubmed-meshheading:19533262-Prosthesis Failure, pubmed-meshheading:19533262-Reoperation, pubmed-meshheading:19533262-Surface Properties, pubmed-meshheading:19533262-Time Factors
pubmed:year
2010
pubmed:articleTitle
Revision total hip arthroplasty with a porous-coated modular stem: 5 to 10 years follow-up.
pubmed:affiliation
Orthopedic Department, Division of Arthroplasty, Mount Sinai Hospital, 600 University Avenue, Suite 476A, Toronto, Ontario M5G 1X5, Canada. drorale@gmail.com
pubmed:publicationType
Journal Article, Comparative Study